Abstract
Nivolumab plus ipilimumab (NIVO+IPI) and pembrolizumab plus axitinib (PEM+AXI) received US FDA approval in 2018 and 2019, respectively, as first-line (1L) therapy for patients (pts) with aRCC, with superior efficacy versus sunitinib. This real-world study assessed characteristics, clinical outcomes, and safety profiles of aRCC pts receiving each 1L regimen at nonacademic US practices.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
